Retrospective analysis of treatment pathways in patients with BRAF(V600E)-mutant metastatic colorectal carcinoma – MORSECRC

Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Akhoundova, D; Maas, C; Uhlig, J; Fenchel, K; Greil, R; von der Heyde, E; Agocs, R; Weide, R; Modest, DP; Fritsch, R ONCOL RES TREAT. 2020; 43(SUPPL 4): 131-131.

Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial

Bianchini, G; Huang, CS; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Russo, S; Ciruelos, EM; Greil, R; Semiglazov, V; Colleoni, MA; Kelly, CM; Mariani, G; Del Mastro, L; Smart, C; Valagussa, P; Viale, G; Gianni, L ANN ONCOL. 2020; 31: S1145-S1146.

Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma

Lordick, F; Chao, J; Buxo, E; van Laarhoven, HWM; Lima, CMR; Lorenzen, S; Dayyani, F; Heinemann, V; Greil, R; Stienen, S; Shitara, K ANN ONCOL. 2020; 31: S928-S929.

The role of Ca15-3 in the follow-up care of early breast cancer patients

Zapf, K; Weiss, R; De Pellegrin, L; Hofer, S; Rinnerthaler, G; Hauser-Kronberger, C; Reitsamer, R; Greil, R; Gampenrieder, SP ONCOL RES TREAT. 2020; 43(SUPPL 4): 162-162.

FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis

Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A ONCOL RES TREAT. 2020; 43(SUPPL 4): 215-215.

Real-world data for immune checkpoint inhibitor therapy as first line treatment of recurrent or metastatic squamous cell cancer of the head and neck

Wagner, SM; Magnes, T; Minichsdorfer, C; Gamerith, G; Pall, G; Greil, R; Melchardt, T; Fureder, T ONCOL RES TREAT. 2020; 43(SUPPL 4): 132-133.

FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis

Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A WIEN KLIN WOCHENSCHR. 2020; 132(SUPPL 2): 78-79.

Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Greil, R; Rischin, D; Harrington, KJ; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Lin, J; Swaby, RF; Gumuscu, B; Burtness, B ANN ONCOL. 2020; 31: S660-S661.

TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia

Hartmann, TN; Szenes, E; Polcik, L; Decker, S; Haslauer, T; Pischeli, J; Kissel, S; Hopner, JP; Egle, A; Zaborsky, N; Dierks, C; Greil, R; Gattei, V; Harzschel, A ONCOL RES TREAT. 2020; 43(SUPPL 4): 70-70.

Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis

Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A ANN ONCOL. 2020; 31: S942-S942.